Physician profile
Sumit M Patel
NPI 1255695011
$5,220.41
in general payments reported to CMS, 2019-2025
31 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $79.85 · 2021: $149 · 2022: $1,911 · 2023: $898 · 2024: $1,055 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medwest Associates | $1,200.00 | 2022 | |
| Glaxosmithkline, LLC. | $813.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $474.99 | 2022-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $438.03 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Grifols USA, LLC | $231.59 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $218.04 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.69 | 2020-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Genzyme Corporation | $164.73 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $163.28 | 2022-2025 | Glassia |
| Mylan Specialty L.P. | $154.63 | 2021-2024 | Yupelri |
| Baxter Healthcare | $138.37 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Pulmonx Corporation | $120.80 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Jazz Pharmaceuticals INC. | $114.69 | 2021-2022 | |
| Allergan, INC. | $99.12 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $88.87 | 2022-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $75.43 | 2021-2024 | |
| Electromed, INC. | $73.33 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $71.89 | 2022-2023 | Uptravi, Opsumit |
| Philips North America LLC | $71.45 | 2023-2024 | (Ak6) Vest Therapy |
| Mallinckrodt Hospital Products INC. | $56.03 | 2022-2024 | Acthar |
| Verona Pharma, INC. | $47.29 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $40.47 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $36.50 | 2019 | |
| Stryker Corporation | $30.27 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $19.91 | 2024 | Tezspire |
| Viatris Specialty LLC | $19.67 | 2025 | Yupelri |
| Advanced Respiratory, INC | $18.24 | 2021 | |
| Genentech USA, INC. | $17.55 | 2020 | |
| Inari Medical, INC. | $16.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Teva Pharmaceuticals USA, INC. | $15.43 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.